Podcasts about considerations

In this episode, Will Van Derveer, MD joins to unpack what we know about which psychedelic medicines are best suited to particular mental health conditions. Dr. Van Derveer has trained several thousand mental health professionals in psychedelic-assisted psychotherapy, provided ketamine assisted therapy to hundreds of people, and has staffed MDMA therapy trials with MAPS. His book, Psychedelic Therapy: A Revolutionary Approach to Restoring Your Mental Health and Reclaiming Your Life, will be published by Shambala in the spring of 2026. In this conversation, Dr. Van Derveer offers a clinician's framework for thinking through how different psychedelic medicines may align with different mental health conditions. He explores how factors such as anxiety levels, trauma history, prior psychedelic experience, and a person's orientation toward spiritual versus medical healing shape treatment decisions. Across discussions of anxiety, depression, PTSD, OCD, and eating disorders, Dr. Van Derveer reflects on the relative roles of ketamine, psilocybin, MDMA, and emerging short-acting psychedelics, while underscoring the importance of community, and integration. Throughout, he returns to a central theme: many conditions labeled as psychiatric may also reflect deeper forms of disconnection—social, existential, and spiritual—and psychedelic therapies can be powerful tools for restoring those lost connections when used thoughtfully.   In this episode, you'll hear: Why safety, medication interactions, and psychiatric history must come before all other considerations The difference between clinical and ceremonial approaches to psychedelic healing Considering when group versus individual approaches to psychedelic therapy may be best suited for a particular patient How ketamine, psilocybin, and MDMA may play distinct roles in treating anxiety and depression Considerations of dose, tolerance, and maintenance sessions for ketamine treatments Why MDMA-assisted therapy stands out for chronic and severe PTSD Dr. Van Derveer's perspective on emerging psychedelic medicines and the future of treatment   Quotes: "As time wears on, I lean more toward the group dynamic [for psychedelic therapy] because of the power of community and healing in community. And also, of course, it can help mitigate the cost of access for people." [8:24] "There's a lot of conversation about ibogaine right now, and I think it's an incredibly powerful, beautiful, sacred, ancient medicine that has a role. But it has a lot more porcupine quills on it than, say, ketamine or MDMA." [27:16] "In acute suicidality, I think ketamine is the treatment of choice. There's nothing like it. … it can be quite impressive how quickly suicidal thoughts melt away. But it is a short game because often it doesn't stick for people. And that's a huge drawback." [28:39] "We know that there are clear associations between chronic depression and high levels of inflammation in the body and also in the brain. Ketamine and psilocybin both have strong anti-inflammatory effects. But it seems like somehow the pathways that psilocybin is working on… tends to produce longer term benefits." [30:10] "I tend to think that spiritual connection—in whatever your language is, whatever your metaphors are, however you think about it—is something that we need to think about for health overall." [40:21]   Links: Dr. Van Derveer on LinkedIn Dr. Van Derveer on Instagram Dr. Van Derveer on X Dr. Van Derveer's forthcoming book, Psychedelic Therapy: A Revolutionary Approach to Restoring Your Mental Health and Reclaiming Your Life Integrative Psychiatry Institution website  Previous episode: Is Psilocybin Safe for Me? with Seth Mehr, MD Psychedelic Medicine Association Porangui

In this episode of the Gladden Longevity Podcast, Dr. Jeffrey Gladden and Dr. Dan Pardi delve into the intricate relationship between longevity, cognitive enhancement, sleep, and stem cell health. They explore the science behind nootropics, the impact of sleep on cognitive function, and the role of stem cells in aging. The conversation highlights the importance of a healthy internal environment and the interplay of various biological systems in promoting longevity. They also discuss innovative approaches to support stem cell function and the significance of mindset in the healing process.     For Audience ·       Use code 'Podcast10' to get 10% OFF on any of our supplements at https://gladdenlongevityshop.com/ !  ·       Get discount using the link ➡️ www.qualialife.com/gladden15     Takeaways ·       The quest for longevity involves understanding how to live young for a lifetime. ·       Nootropics can enhance cognitive function and overall brain health. ·       Sleep is crucial for recovery and cognitive performance. ·       GHB has potential benefits for promoting deep sleep and recovery. ·       Stem cell health is vital for combating the effects of aging. ·       The hallmarks of aging are interconnected and influence each other. ·       Creating a supportive environment for stem cells can enhance their function. ·       Mindset and relaxation techniques can significantly impact healing. ·       Innovative products are being developed to support stem cell health. ·       Integrating various health strategies can lead to better longevity outcomes.   Chapters 00:00 Introduction to Qualia and Nootropics 05:31 The Science Behind Nootropics 08:22 Dan Pardee's Journey and PhD Focus 10:58 Understanding Narcolepsy and Sodium Oxybate 13:41 The Role of Sleep in Health 16:13 Exploring the Therapeutic Potential of Sodium Oxybate 18:57 Challenges and Considerations in Sleep Medicine 21:47 Stem Cell Innovations at Qualia 24:40 Understanding Stem Cell Exhaustion and Aging 27:01 The Interplay of Aging Hallmarks 29:55 The Exponential Nature of Aging 31:46 Strategies for Stem Cell Health 38:21 Clearing Senescent Cells for Regeneration 43:30 The Role of Mindfulness in Healing   To learn more about Dan Pardi: Email:  dan@qualialife.com Website: www.qualialife.com Facebook: https://www.facebook.com/Qualialife Instagram: https://www.instagram.com/qualialife/   Reach out to us at:    Website: https://gladdenlongevity.com/     Facebook: https://www.facebook.com/Gladdenlongevity/    Instagram: https://www.instagram.com/gladdenlongevity/?hl=en     LinkedIn: https://www.linkedin.com/company/gladdenlongevity    YouTube: https://www.youtube.com/channel/UC5_q8nexY4K5ilgFnKm7naw         Gladden Longevity Podcast Disclosures Production & Independence The Gladden Longevity Podcast and Age Hackers are produced by Gladden Longevity Podcast, which operates independently from Dr. Jeffrey Gladden's clinical practice and research at Gladden Longevity in Irving, Texas. Dr. Gladden may serve as a founder, advisor, or investor in select health, wellness, or longevity-related ventures. These may occasionally be referenced in podcast discussions when relevant to educational topics. Any such mentions are for informational purposes only and do not constitute endorsements. Medical Disclaimer The Gladden Longevity Podcast is intended for educational and informational purposes only. It does not constitute the practice of medicine, nursing, or other professional healthcare services — including the giving of medical advice — and no doctor–patient relationship is formed through this podcast or its associated content. The information shared on this podcast, including opinions, research discussions, and referenced materials, is not intended to replace or serve as a substitute for professional medical advice, diagnosis, or treatment. Listeners should not disregard or delay seeking medical advice for any condition they may have. Always seek the guidance of a qualified healthcare professional regarding any questions or concerns about your health, medical conditions, or treatment options. Use of information from this podcast and any linked materials is at the listener's own risk. Podcast Guest Disclosures Guests on the Gladden Longevity Podcast may hold financial interests, advisory roles, or ownership stakes in companies, products, or services discussed during their appearance. The views expressed by guests are their own and do not necessarily reflect the opinions or positions of Gladden Longevity, Dr. Jeffrey Gladden, or the production team. Sponsorships & Affiliate Disclosures To support the creation of high-quality educational content, the Gladden Longevity Podcast may include paid sponsorships or affiliate partnerships. Any such partnerships will be clearly identified during episodes or noted in the accompanying show notes. We may receive compensation through affiliate links or sponsorship agreements when products or services are mentioned on the show. However, these partnerships do not influence the opinions, recommendations, or clinical integrity of the information presented. Additional Note on Content Integrity All content is carefully curated to align with our mission of promoting science-based, ethical, and responsible approaches to health, wellness, and longevity. We strive to maintain the highest standards of transparency and educational value in all our communications.

Our Lord's mic drop moment

The importance of daily prayer-we can not give what we do not have

2026 may be the most confusing year for student loans yet. Find out what's actually changing with repayment plans, forgiveness, and Parent PLUS loans — and learn what you should be paying attention to right now. We'll also hear real listener questions about PSLF during a government shutdown, IDR recertification delays, getting out of SAVE forbearance, and whether PSLF buyback is worth counting on. If you're feeling anxious heading into 2026, this episode can help you make smart decisions without overreacting. Key moments: (00:44) Does government shutdown time count for PSLF? (08:26) Moving out of the SAVE forbearance, PSLF buyback and family size rules (20:10) Considerations for filing taxes jointly vs. separately (29:30) Warning for Parent PLUS borrowers who are still borrowing or who haven't yet consolidated (35:31) RAP plan rollout and what borrowers should expect next Like the show? There are several ways you can help! Follow on Apple Podcasts, Spotify or Amazon Music Leave an honest review on Apple Podcasts  Subscribe to the newsletter Join SLP Insiders for student loan loopholes, SLP app and member community Feeling helpless when it comes to your student loans? Try our free student loan calculator Check out our refinancing bonuses we negotiated Book your custom student loan plan Get profession-specific financial planning Do you have a question about student loans? Leave us a voicemail here or email us at help@studentloanplanner.com and we might feature it in an upcoming show!

In this follow-up episode,  Dr. Nikolaos Papadantonakis continues the conversation with Dr. Colin Vale from Winship Cancer Institute of Emory University and Dr. Nancy Luna Torres from Moffitt Cancer Center, diving deeper into advanced transplant topics. This episode is ideal for patients and families who want to understand the nuances of transplant care and post-transplant management.

A saint that didn't let roadblocks get in his way

What's in a gift?

What's in a name?

The humility of John the Baptist

In this episode, I share a recent failure I experienced - one that left me feeling embarrassed, guilty, and stuck in a cycle of shame. I talk about what happened when I published my book "A Consideration a Day," realized it wasn't what I wanted it to be, and then caught myself avoiding this very podcast for weeks because I didn't want to admit my mistake. But here's what changed everything: I walked myself through The unSTUCK Method and chose to get unstuck from the Reactivity Loop instead of staying stuck in it. If you've ever failed at something and found yourself spiraling into negative self-talk, hiding, or taking on guilt that doesn't serve you - this episode is for you. Listen to hear how I moved from stuck to unstuck, and how you can too. Sign up for the upcoming 3-Day Challenge: www.shiragura.com

Listen on YouTube it's the Christmas Special! Luke and Michael share a love for the 1983 film starring Matthew Broderick and Ally Sheedy. T-shirts can be found here – https://www.redbubble.com/people/ufocast Follow us on twitter @ufo_cast Like us on Facebook Review us on iTunes Email the show – ufocast@yahoo.com

The prayer, the power, and the promises of the Holy Rosary

He tabernacled among us

What desire is taking too much weight in your life?

Listen to #Pulse95Radio in the UAE by tuning in on your radio (95.00 FM) or online on our website: www.pulse95radio.com ************************ Follow us on Social. www.instagram.com/pulse95radio www.facebook.com/pulse95radio www.twitter.com/pulse95radio

Ken Carman and Anthony Lima talk about Kevin Stefanski's future and if things have changed after the win over the Steelers. Then they discuss if the sack record will be respected if Myles Garrett gets it in 17 games before getting into Lima Likes.

Ken Carman and Anthony Lima talk about if there's an argument to be made for the Browns to keep Kevin Stefanski after the win over the Steelers.

In this episode of The Crux True Survival Stories, host Kaycee McIntosh interviews Dr. Mitchell Seruya, a board-certified plastic surgeon and peripheral nerve specialist at Cedars Sinai Medical Center. Dr. Seruya discusses his pioneering work in nerve surgery, including groundbreaking procedures that offer new hope to patients with paralysis and chronic pain. He shares his journey into medicine, the intricacies of his surgical techniques, and the remarkable recoveries of his patients, including a first-of-its-kind surgery for a previous guest. The conversation delves into the future of nerve surgery and the potential for advanced prosthetics and stem cell therapies. Dr. Seruya also emphasizes the importance of gratitude, mindset, and the spiritual aspect of healing in his practice. 00:00 Introduction to Dr. Mitchell Seruya 01:23 Dr. Seruya's Career Path and Inspirations 02:43 Understanding Nerve Injuries and Surgeries 04:09 The Impact of Nerve Surgeries 06:22 Dr. Seruya's Hollywood Experience 08:38 Common Nerve Injuries and Treatments 11:34 Nerve Grafting and Transfer Techniques 16:32 Challenges and Considerations in Nerve Surgery 19:29 Personal Practice and Cadaver Nerve Usage 19:51 Theresa's Unique Case and Surgical Approach 21:09 Innovative Nerve Rerouting Techniques 25:42 Post-Surgery Recovery and Patient Mindset 31:18 Time Sensitivity in Nerve Damage Treatment 33:12 Future of Nerve Transplant Surgery 35:40 Addressing Chronic Nerve Pain 38:18 Training and Collaboration in Peripheral Nerve Surgery 39:33 Finding the Right Specialist 40:22 Closing Remarks and Gratitude https://www.cedars-sinai.org/provider/mitchel-seruya-2624729.html Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Another gem from the book of Sirach on honoring you Father and Mother

First there but last in!

Like our Lord, Stephen dies praying for and forgiving his executioners

EV manufacturing growth, industrial digitalisation and sustainability priorities are elevating Tanjong Malim's profile in Malaysia and Southeast Asia's data centre planning. Five located plots at Sungai Samak Estate present developers an opportunity to establish integrated, next generation data centres within an emerging high-technology manufacturing ecosystem. Sungai Samak Estate City: Kuala Lumpur Address: 2 Jalan Sempurna off Jalan Gombak Website: https://sgsamak.com

The 3 reasons God became man

it's the Christmas Special! Luke and Michael share a love for the 1983 film starring Matthew Broderick and Ally Sheedy.

The culmination of the entire old covenant

For the end of the year, we're doing a countdown of the most listened-to episodes of the orthoPAc podcast! Carmen Quatman, MD, PhD, is an orthopedic surgeon specializing in trauma care, with fellowship training in geriatric orthopedic trauma. In part one of a two part interview, she discusses important considerations for geriatric patients, to better help them be safe at home and have as high a quality of life as possible.

They were filled with fear!

How great THOU art

Mortgage headlines are loud again. Between talk of 50-year mortgages, the FHFA revisiting assumable and portable loans, and lenders raising questions about feasibility, there's a lot of noise on how this will affect the housing market, but few are talking about what this means for investors, specifically.In this week's Not Your Average Insights, JWB Co-Founder Gregg Cohen and host Pablo Gonzalez break down what is happening and add the investor's perspective.They'll unpack:- Why 50-year mortgages look different from an investor's perspective, and may be a momentary opportunity you need to be prepared for- How portable and assumable mortgage ideas could reshape mobility, and trigger local regulations risk- What these policies tell us about how different real estate is as an asset class for retail investorsIf you read the typical articles about these topics and didn't find any useful insights- especially if you were one of the many community members that sent us one- this show is for you!Listen NOW!Chapters:00:00 Introduction and Welcome02:19 Summit Announcement and Details09:49 Discussion on 50-Year Mortgages11:07 Historical Context of Mortgages20:16 Investor Perspective on 50-Year Mortgages24:42 Inflation Profiting Explained31:26 The Kicker: Real Estate as a Wealth Building Tool32:40 The 50-Year Mortgage: A Deep Dive33:55 Comparing 30-Year and 50-Year Mortgages37:23 Challenges and Considerations of 50-Year Mortgages39:33 Portable Mortgages: A New Concept45:03 Addressing Housing Affordability53:22 Q&A Session: Real Estate Insights01:01:54 Final Thoughts and TakeawaysStay connected to us! Join our real estate investor community LIVE: https://jwbrealestatecapital.com/nyai/Schedule a Turnkey strategy call: https://jwbrealestatecapital.com/turnkey/ *Get social with us:*Subscribe to our channel  @notyouraverageinvestor  Subscribe to  @JWBRealEstateCompanies  

Mallory Willsea sits down with David Weil, SVP for Strategic Services and CIO at Ithaca College, to unpack a bold thesis from his recent EDUCAUSE article. The two dive deep into how AI's most transformative potential in higher education isn't found in flashy tools or automations — it's in building a longitudinal view of the student experience. From data ethics and institutional silos to retention strategies and responsible design, this conversation challenges the status quo and outlines a human-first path forward for AI in higher ed.David's Article: Three Years In: Reflections and Considerations for the Next Chapter of AI in Higher Education - - - -Connect With Our Host:Mallory Willsea https://www.linkedin.com/in/mallorywillsea/https://twitter.com/mallorywillseaAbout The Enrollify Podcast Network:The Higher Ed Pulse is a part of the Enrollify Podcast Network. If you like this podcast, chances are you'll like other Enrollify shows too!Enrollify is made possible by Element451 — The AI Workforce Platform for Higher Ed. Learn more at element451.com. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Joseph, you da man!

The post Consideration, Revelation, and Obedience appeared first on Providence Church.

The greatest choice ever made

"The thought of recurrence is also a psychosocial issue for our patients. They're being monitored very closely for five years, so there's always that thought in the back of their head, 'What if the cancer comes back? What are the next steps? What am I going to do next?' It's really important that we have conversations with patients and their families about where they're at, what we're looking for, and reassure them that we'll be with them during this journey and help them through whatever next steps happen," ONS member Clara Beaver, DNP, RN, AOCNS®, ACNS-BC, manager of clinical education and clinical nurse specialist at Karmanos Cancer Institute in Detroit, MI, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about prostate cancer survivorship considerations for nurses. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by December 19, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to survivorship nursing considerations for people with prostate cancer. Episode Notes  Complete this evaluation for free NCPD. ONS Podcast™ episodes: Episode 390: Prostate Cancer Treatment Considerations for Nurses Episode 387: Prostate Cancer Screening, Early Detection, and Disparities Episode 201: Which Survivorship Care Model Is Right for Your Patient? Episode 194: Sex Is a Component of Patient-Centered Care ONS Voice articles: APRNs Collaborate With PCPs on Shared Survivorship Care Models Exercise Before ADT Treatment Reduces Rate of Side Effects Frank Conversations Enhance Sexual and Reproductive Health Support During Cancer Here Are the Current Nutrition and Physical Activity Recommendations for Cancer Survivors Nursing Considerations for Prostate Cancer Survivorship Care Regular Physical Activity and Healthy Diet Lower Risk of All-Cause and Cardiac Mortality in Prostate Cancer Survivors Sexual Considerations for Patients With Cancer Sleep Disturbance Is Part of a Behavioral Symptom Cluster in Prostate Cancer Survivors ONS course: Essentials in Survivorship Care for the Advanced Practice Provider Clinical Journal of Oncology Nursing articles: A Patient-Specific, Goal-Oriented Exercise Algorithm for Men Receiving Androgen Deprivation Therapy Incorporating Nurse Navigation to Improve Cancer Survivorship Care Plan Delivery Prostate Cancer: Survivorship Care Case Study, Care Plan, and Commentaries The Role of the Advanced Practice Provider in Bone Health Management for the Prostate Cancer Population Oncology Nursing Forum articles: A Qualitative Exploration of Prostate Cancer Survivors Experiencing Psychological Distress: Loss of Self, Function, Connection, and Control Identification of Symptom Profiles in Prostate Cancer Survivors Sleep Hygiene Education, ReadiWatch™ Actigraphy, and Telehealth Cognitive Behavioral Training for Insomnia for People With Prostate Cancer Understanding Men's Experiences With Prostate Cancer Stigma: A Qualitative Study Other ONS resources: Late Effects of Cancer Treatment Huddle Card Survivorship Care Plan Huddle Card Survivorship Learning Library American Cancer Society (ACS): Living as a Prostate Cancer Survivor ACS prostate cancer survivorship studies To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "Some of the most common late side effects [are] urinary, bowel, and sexual dysfunction issues. For urinary effects, it can include urgency and frequency, some incontinence, or a weak or slow urine stream that frequently bothers the patient after treatment. Bowel effects can happen such as constipation, diarrhea, or inflammation of the rectum, which can lead to bleeding or mucus discharge. And then erectile dysfunction is another side effect that patients with prostate cancer often deal with and have to work with their physicians on, depending on what they want with that function. Fatigue, lymphedema, and skin changes can also occur after treatment." TS 1:40 "If we can catch [prostate cancer] and take care of it at an early stage, overall survival is about 90%. If the disease is localized, it's 99%. If we can take out the prostate, radiate the prostate, we can do something with that—localized, 99% survival rate. If there's regional metastasis, it's about 90%. And if there's distant metastasis, it's about 30% survival." TS 3:55 "Prostate cancer recurs in about 20%–30% of patients within the first five years of initial treatment. ... There's not a lot of research out there that shows what can reduce risk, but what has been shown to be effective is regular exercise, quitting smoking, and eating a healthy diet. ... It's really important for our patients to understand the importance of having follow-up visits so that we can catch a recurrence quickly instead of waiting years down the road. Prostate cancer is usually a slow-growing disease, so if we can pick it up quickly in those revisits, we can start another treatment for the patient." TS 6:00 "Sexuality is not something many people are comfortable discussing, but we really need to talk with patients and let them know that this is normal. It is normal that you may have some sexual dysfunction. It's normal that you may not feel the way you did before. Talk to us about it, let us know where you're at, let us know what your goals are, because there are a lot of things we can do. There are medications we can use for impedance. There are devices and implants available to help the patient to support them and give them whatever their goal is for their sexuality." TS 9:41 "Providing survivorship care plans are important for these patients—something that can be sent off to everyone else that's caring for that patient. You have your primary care physician, urologist, oncologist, the oncology nurse, maybe a navigator, and [others] who are looking into this patient. So, giving that patient a survivor care plan and putting it with their files to include a summary of the treatment received, because most of the time a patient is not going to remember exactly what they received. A suggested schedule for follow-up exams—so again, if a primary care provider is not used to dealing with a patient with prostate cancer, they have something to go off of. A schedule of other tests they may need in the future including screening for other types of cancer. Are they a smoker? Do they need lung screening? Do they need any other screenings related to types of cancers? And then a list of possible late or long-term side effects." TS 15:16 "I think a lot of people know about the long-term sexual effects, but what we don't really talk about is the effect that it has on the patient's self-image. How they define themselves, how they look, their body image, their self-image. It's really important that we continue to discuss it with patients and make them comfortable when discussing their sexuality and their goals for sexuality. They may be having these self-image issues after treatment that they're just not telling us about and that can affect their quality of life." TS 18:38

Feeling under qualified for the job

On Episode 91 of the Land to Lots Podcast, Part 1 of a two-part conversation, Carter interviews Ross Martin, Shareholder at Winstead PC and one of Texas' leading public finance attorneys advising developers on MUDs, MMDs, PIDs, TIRZs, and other district financing tools. Ross explains the rise of Municipal Management Districts in Texas, why they were created, and how they function within the state's broader district framework. Carter and Ross discuss the statutory foundation for MMDs, the problems they were designed to solve, and the ways in which they can provide meaningful advantages for both cities and developers. Ross also outlines the structural differences between MMDs and MUDs, key governance considerations, and the issues practitioners must account for during formation. In this episode you'll learn: What an MMD is, why the statute was adopted, and the challenges it was designed to address. How MMDs and MUDs differ in authority, governance, eligible public improvements, bond types, and long-term responsibilities. How cities view MMDs within their boundaries and when an MMD may be preferred over a PID, PID/TIRZ, or in-city MUD. Considerations when evaluating an MMD versus a MUD in unincorporated county areas. Key advantages and limitations of MMDs from a developer's perspective. Examples of innovative financing structures using MMDs and why they were effective. Common formation and issuance pitfalls and how to avoid them. The most significant changes Ross has seen in the private sector's use of special districts over the past 20 years. Show NotesRoss Martin – Contact InformationO – 214.745.5353 W – https://www.winstead.com/People/Ross-Martin E – rmartin@winstead.com Plus: Whenever you're ready here are 4 ways Launch can help you with your project: Prepare a Special Tax District Bond Analysis for your Project – If you have a projects in AZ, CA, CO, ID, NC, NM, SC, TN, TX, UT, WA contact  Carter Froelich (ADD MY EMAIL LINK) and have Launch prepare an initial bond analysis for your project. Add Favorable Financing Language to Annexation and/or Development Agreements – Create certainty and flexibility related to your project's infrastructure financing by having Launch professionals prepare handcrafted favorable financing language for inclusion in your Annexation and/or Development Agreement. Perform The RED Analysis™ on your Project – We have developed a unique process at Launch called The RED Analysis™ in which we perform a diagnostic review of your project to determine possible ways to Reduce, Eliminate and Defer infrastructure construction costs in order to enhance project returns. Track Your Reimbursable Costs Utilizing The Launch Reimbursement System™ ("LRS") – Never lose track of your district eligible reimbursable costs and have Launch manage your district's costs reimbursement tracking, preparation of electronic reimbursement submittal packages and processing of your reimbursement requests with the district, jurisdiction and/or agency. Complimentary Offers for Land to Lots™ ListenersComplimentary Land to Lots book: https://www.launch-mpc.com/offer Complimentary Bond Sizing Analysis:  https://form.jotform.com/231376408765160 Carter Froelich hosts the Land to Lots™ podcast powered by Launch Development Finance Advisors. Carter shares how he and his team help their clients finance infrastructure, reduce costs, and mitigate risks all with the goal of enhancing project profitability Land to Lots™ is a registered trademark of Launch Development Finance Advisors

Nick van Eck is the CoFounder and CEO at Agora.In this episode, Nick explains why he believes stablecoins are entering their "second inning," how enterprises are beginning to adopt stablecoins at scale, and what it actually takes to build payment infrastructure that operates at the speed of the internet.------

In this episode, the CardioNerds (Dr. Natalie Tapaskar, Dr. Jenna Skowronski, and Dr. Shazli Khan) discuss the process of heart transplantation from the initial donor selection to the time a patient is discharged with Dr. Dave Kaczorowski and Dr. Jason Katz. We dissect a case where we understand criteria for donor selection, the differences between DBD and DCD organ donors, the choice of vasoactive agents in the post-operative period, complications such as cardiac tamponade, and the choice of immunosuppression in the immediate post-operative period. Most importantly, we highlight the importance of multi-disciplinary teams in the care of transplant patients. Audio editing for this episode was performed by CardioNerds Intern, Dr. Julia Marques Fernandes. Enjoy this Circulation 2022 Paths to Discovery article to learn about the CardioNerds story, mission, and values. CardioNerds Heart Success Series PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! Pearls When thinking about donor selection, you need to consider how much physiologic stress your recipient can tolerate, and this may guide your selection of “higher risk” or “lower risk” donors.   The use of DCD donors has increased the potential donor pool and shortened waitlist times with very similar perioperative outcomes to DBD transplantation.  Post-operative critical care management rests on a fundamental principle to apply as much inotropic/vasoactive therapy as needed to achieve some reasonable physiologic hemostasis, and then getting “the heck out of the way!” There are no standard regimens as practices vary across centers, but rest on providing adequate RV support, maintaining AV synchrony, and early resuscitation.   The RV is fickle and doesn't take a joke too well. RV dysfunction post-transplant is important to watch for, and it can be transient or require aggressive support. Don't miss assessing for cardiac tamponade which can require surgical evacuation- “where there's space, that space can be filled with fluid.”   Induction immunosuppression post-transplant varies across centers, but some considerations for use may include (1) high sensitization of the patient, (2) high risk immunologic donor-recipient matching, and (3) recipient renal dysfunction to provide a calcineurin inhibitor (CNI) sparing regimen long term.  Management of heart transplant patients is a multi-disciplinary effort that requires coordination amongst heart failure/transplant cardiologists, cardiac surgeons, anesthesiologists, pathology/immunologists and a slew of ancillary services. Without a dynamic and collaborative team, successful cardiac transplantation could not be possible.  Notes Notes: Notes drafted by Dr. Natalie Tapaskar  What are the basic components of donor heart selection? In practicality, it can be a very inexact science, but we use some basic selection criteria such as: (1) size matching (2) ischemic time (3) donor graft function (4) immunologic compatibility (5) age of the potential donor and recipient (6) severity of illness of the recipient (7) regional variation in donor availability When thinking about accepting older donors (>50 years old), we ideally would screen for donor coronary disease and try to keep ischemic times as short as possible. We may accept an older donor for a recipient who is highly sensitized, which leaves a smaller potential donor pool. There is no clear consensus on size matching, but the predicted heart mass is most used. We are generally more comfortable oversizing than under-sizing donor hearts. Serial echocardiography is important in potential donors as initially reduced ejection fractions can improve on repeat testing, and these organs should not be disregarded automatically. For recipients who are more surgically complex, (i.e. multiple prior sternotomies or complex anatomy), it's probably preferable to avoid older donors with some graft dysfunction and favor donors with shorter ischemic times. What is the difference between DBD and DCD? DBD is donation after brain death- these donors meet criteria for brain death. Uniform Determination of Death Act 1980: the death of an individual is The irreversible cessation of circulatory and respiratory functions or The irreversible cessation of all functions of the entire brain, including those of the brain stem DCD is donation after circulatory death- donation of the heart after confirming that circulatory function has irreversibly ceased. Only donors in category 3 of the Maastricht Classification of DCD donors are considered for DCD donations: anticipated circulatory arrest (planned withdrawal of life-support treatment). DCD hearts can be procured via direct procurement or normothermic regional perfusion (NRP). The basic difference is the way the hearts are assessed, either on an external circuit or in the donor body. For the most complex recipient, DCD may not be utilized at some centers due to concern for higher rates of delayed graft function, but this is center specific and data is still evolving. What are some features surgeons consider when procuring the donor heart? Visual assessment of the donor heart is key in DBD or NRP cases. LV function may be hard to assess, but visually the RV can be inspected. Palpation of the coronary arteries is important to assess any calcifications or abnormalities. Ventricular arrhythmias at the time of procurement may be concerning. Key considerations in the procurement process: (1) Ensuring the heart remains decompressed at all times and doesn't become distended (2) adequate cardioplegia delivery (3) aorta is cross-clamped properly all the way across the vessel (4) avoiding injury to adjacent structures during procurement What hemodynamic parameters should we monitor and what vasoactive agents are used peri-heart transplant? There is no consensus regarding vasoactive agent use post-transplant and practice varies across institutions. Some commonly seen regimens may include: (1) AAI pacing around 110 bpm to support RV function and preserve AV synchrony (2) inotropic agents such as epinephrine and dobutamine to support RV function (3) pulmonary vasodilators such as inhaled nitric oxide to optimize RV afterload Early post-transplant patients tend to have low cardiac filling pressures and require preload monitoring and resuscitation initially. Slow weaning of inotropes as the patient shows signs of stable graft function and hemodynamics. RV dysfunction may manifest as elevated central venous pressure with low cardiac index or hypotension with reducing urine output. Optimize inotropic support, volume status, metabolic status (acidosis and hypoxia), afterload (pulmonary hypertension), and assess for cardiac tamponade. Tamponade requires urgent take-back to the operating room to evacuate material. Refractory RV failure requires mechanical circulatory support, with early consideration of VA-ECMO. Isolated RV MCS may be used in the right clinical context. Why do pericardial effusions/cardiac tamponade happen after transplant? They are not uncommon after transplant and can be due to: Inherent size differences between the donor and recipient (i.e. if the donor heart is much smaller than the recipient's original heart) Bleeding from suture lines and anastomoses, pacing wires, and cannulation sites Depending on the hemodynamic stability of the patient and the location of the effusion, these effusions may require urgent return to the OR for drainage/clot evacuation via reopening the sternotomy, mini thoracotomy, and possible pericardial windows. What are the basics of immunosuppression post-transplant? Induction immunosuppression is variably used and is center-specific. Considerations for using induction therapy may include: (1) high sensitization of the patient (2) younger patients or multiparous women with theoretically more robust immune systems (3) crossing of recipient antibodies with donor antigens (3) renal function to provide a CNI sparing regimen long term Some considerations for avoiding induction may include: (1) older age of the recipient (2) underlying comorbid conditions such as infections or frailty of the recipient What are expected activity restrictions post-transplant? Sternal precautions are important to maintain sternal wire integrity. Generally avoiding lifting >10 pounds in the first 4-12 weeks, no driving usually in the first 4 weeks, monitoring for signs and symptoms of wound infections, and optimizing nutrition and physical activity. Cardiac rehabilitation is incredibly important as soon as feasible. References Kharawala A , Nagraj S , Seo J , et al. Donation after circulatory death heart transplant: current state and future directions. Circ: Heart Failure. 2024;17(7). doi: 10.1161/circheartfailure.124.011678  Copeland H, Knezevic I, Baran DA, et al. Donor heart selection: Evidence-based guidelines for providers. The Journal of Heart and Lung Transplantation. 2023;42(1):7-29. doi:10.1016/j.healun.2022.08.030  Moayedifar R, Shudo Y, Kawabori M, et al. Recipient Outcomes With Extended Criteria Donors Using Advanced Heart Preservation: An Analysis of the GUARDIAN-Heart Registry. J Heart Lung Transplant. 2024;43(4):673-680. doi:10.1016/j.healun.2023.12.013  Kharawala A, Nagraj S, Seo J, et al. Donation After Circulatory Death Heart Transplant: Current State and Future Directions. Circ Heart Fail. 2024;17(7):e011678. doi:10.1161/CIRCHEARTFAILURE.124.011678  Copeland H, Hayanga JWA, Neyrinck A, et al. Donor heart and lung procurement: A consensus statement. J Heart Lung Transplant. 2020;39(6):501-517.

Saying yes but doing no

Welcome to the Oncology Brothers podcast! In this episode, we were joined by Dr. Rutika Mehta, a GI medical oncologist from Weill Cornell. Together, we dived into the current treatment landscape for advanced metastatic gastroesophageal junction (GEJ) and gastrointestinal carcinoma, with a special focus on HER2-positive disease. Episode Highlights: • Overview of recent advancements in the treatment of resectable disease, including the approval of Durvalumab in perioperative settings. • Discussion on the importance of biomarker testing, including HER2, PD-L1, MMR, and Claudin 18.2, in determining treatment options. • Insights into frontline treatment strategies for HER2-positive patients, including the role of trastuzumab and the addition of pembrolizumab based on PD-L1 status. • The significance of retesting HER2 expression upon disease progression and the implications for treatment decisions. • Exploration of emerging therapies like TDXd and Zanidatamab, and their potential impact on the treatment landscape. • Considerations for managing side effects and the importance of treatment sequencing in palliative care. Join us for an informative discussion that aims to keep community oncologists up to date in this ever-evolving field of cancer treatment. Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to subscribe for more episodes covering treatment algorithms, FDA approvals, and conference highlights! Accreditation/Credit Designation Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Physicians' Education Resource®, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Acknowledgment of Commercial Support This activity is supported by an educational grant from Jazz Pharmaceuticals, Inc. Link to gain CME credits from this activity: https://www.gotoper.com/courses/biomarker-testing-in-her2-gea-diagnosis-and-treatment-implications    #HER2GastricCancer #GastricCancer #BiomarkerTesting #OncologyBrothers #GIOncology #CME

BDSM and kinky sex relationships are no different then non-kinky relationships when it comes to considering the feelings of your partners. Selfish people suck in all walks of life, and expectations can be unrealistic. We kink talk about these and other sexy topics every other week! Perverted Podcast!

Michigan's Next Head Coach? Evaluating the Top ContendersIn this episode of the Buckeye Weekly Podcast, hosts Tony Gerdeman and Tom Orr discuss their top picks for the most realistic candidates to become Michigan's next head coach. As they dig deep into the potential hires, they analyze recent statements from Kalen DeBoer and Kenny Dillingham, and consider other options like Jedd Fisch and Kyle Whittingham. The hosts also delve into the challenges and complexities accompanying the coaching search, given the ongoing investigations and administrative changes at Michigan. Join the conversation as they provide insights into who could potentially take the reins of the Michigan football program.00:00 Introduction and Podcast Overview00:14 Breaking News: Kalen DeBoer's Statement01:08 Analyzing Coaching Statements02:35 Potential Candidates for Michigan Job04:42 Jedd Fisch: The Next Likely Candidate07:53 Challenges and Considerations for Michigan's Next Coach15:03 Kyle Whittingham: A Surprising Contender20:47 Conclusion and Final Thoughts

What kills our joy and how to keep it

We need to pray for more prophets!

In this episode, we explore pharmacologic treatment for postpartum depression in breastfeeding mothers. Can psychiatric medications be safely used while nursing? Dr. Lauren Osborne explains how nearly all antidepressants are compatible with breastfeeding, why postpartum women may respond faster to treatment, and how to choose the right medication. Faculty: Lauren Osborne, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1.25 CME: Understanding Postpartum Mood Disorders: A Comprehensive Guide Postpartum Depression: Pharmacologic Considerations for Breastfeeding Mothers

"I'll go back to the backpack analogy. When your kids come home with a backpack, all of a sudden their homework is not on the desk where it's supposed to be. It's in the kitchen; it kind of spreads all over the place, but it's still in the house. When we give antibody–drug conjugates (ADCs), the chemotherapy does go in, but then it can kind of permeate out of the cell membrane and something right next to it—another cancer cell that might not look exactly like the cancer cell that the chemotherapy was delivered into—is affected and the chemotherapy goes over to that cancer cell and kills it," ONS member Marisha Pasteris, OCN®, office practice nurse in the breast medicine service at Memorial Sloan Kettering Cancer Center in New York, NY, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about ADCs in metastatic breast cancer. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  This podcast is sponsored by Gilead and is not eligible for NCPD contact hours. ONS is solely responsible for the criteria, objectives, content, quality, and scientific integrity of its programs and publications.  Episode Notes  This episode is not eligible for NCPD. ONS Podcast™ episodes: Episode 391: Pharmacology 101: Antibody–Drug Conjugates Episode 378: Considerations for Adolescent and Young Adult Patients With Metastatic Breast Cancer Episode 368: Best Practices for Challenging Patient Conversations in Metastatic Breast Cancer Episode 350: Breast Cancer Treatment Considerations for Nurses Episode 303: Cancer Symptom Management Basics: Ocular Toxicities ONS Voice articles: An Oncology Nurse's Guide to Cancer-Related Ocular Toxicities Black Patients With Metastatic Breast Cancer Are Less Informed About Their Clinical Trial Options Communication Case Study: Talking to Patients About Progressive Metastatic Breast Cancer What Is HER2-Low Breast Cancer? ONS Voice drug reference sheets: Belantamab mafodotin-blmf Datopotamab deruxtecan-dlnk Enfortumab vedotin-ejfv Fam-trastuzumab deruxtecan-nxki ONS books: Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (second edition) Guide to Breast Care for Oncology Nurses Guide to Cancer Immunotherapy (second edition) ONS courses: ONS Fundamentals of Chemotherapy and Immunotherapy Administration™ ONS/ONCC® Chemotherapy Immunotherapy Certificate™ Clinical Journal of Oncology Nursing article: Antibody–Drug Conjugates and Ocular Toxicity: Nursing, Patient, and Organizational Implications for Care The Association Between Hormone Receptor Status and End-of-Life Care Among Patients With Metastatic Breast Cancer Oncology Nursing Forum article: Impact of Race and Area Deprivation on Triple-Negative Metastatic Breast Cancer Outcomes ONS huddle cards: Altered Body Image Huddle Card Chemotherapy Huddle Card Targeted Therapy Huddle Card Foundations of Antibody–Drug Conjugate Use in Metastatic Breast Cancer: A Case Study ONS Biomarker Database (refine by breast cancer) ONS Breast Cancer Learning Library American Society of Clinical Oncology (ASCO) homepage Drugs@FDA package inserts National Comprehensive Cancer Network homepage Susan G. Komen metastatic breast cancer page To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "What an ADC is doing is taking the antibody and linking it to a cytotoxic chemotherapy with the idea of delivering it directly into the cell. How I explain this to new nurses or patients is a backpack analogy. If we think of it as a HER2 molecule wearing a chemo backpack, it's going to find the HER2 receptor attached to it and then drop the chemotherapy into the cell via the backpack. Similar to how we come home from work, we open the key to our door, we're carrying all of our items, and then we drop our own personal items in our house." TS 2:30 "The reason that so many patients with metastatic breast cancer are able to receive ADC therapy is because they are targeting two very common antibodies that we see in breast cancer. One is HER2 and the other is trophoblast cell surface antigen 2 (TROP2). These are seen across the board. We see these on triple-negative breast cancers, hormone receptor–positive cancers, and HER2-positive breast cancers. And now we have a new way to talk about HER2, which is a HER2-low. ... Recently, we have found that patients who express low levels of HER2 are able to receive ADC therapy, specifically fam-trastuzumab deruxtecan." TS 4:21 "Another [ADC] that has just been approved is datopotamab deruxtecan. This is another ADC that targets the TROP2 receptor on a cancer cell. This one carries a lot of side effects. I mentioned earlier that you need an ophthalmology clearance because there is a lot of ocular toxicity around this one. We see a lot of blepharitis, conjunctivitis, there can be blurred vision. Another thing we monitor on this one is mucositis. In the package insert, there's a recommendation for using ice chips while receiving the treatment. ... Then in the HER2-positive and HER2-low space is the big one, which is fam-trastuzumab deruxtecan. This was approved in 2019 for the HER2-positive patients, then more recently in the HER2-low [patients]. The big [side effect] with this one is interstitial lung disease." TS 10:11 "Interstitial lung disease is an inflammation or a little bit of fibrosis within the lung that causes an impaired exchange between the oxygen and carbon dioxide. This was seen in the clinical trials, specifically around fam-trastuzumab deruxtecan. During the trials, they had a very small percentage, I think it was 1%, that died due to interstitial lung disease. So, this is a very important side effect for us as nurses to be aware of. It typically presents in patients like a dyspnea. A lot of times, it's like, 'Well, I used to be able to walk my kid to the bus stop, but now when I walk there, I feel really short of breath.' Or 'I've had this dry cough for the past couple weeks and I've tried medications, but haven't had that relieved.' So, we really need to be aware of that because early intervention in interstitial lung disease is key." TS 12:57 "ADCs are toxic drugs. They have the benefit of being targeted, but we know that they carry a lot of side effects. ... Their specificity makes them so wonderful and we've seen amazing responses to these drugs. But also, we want patients to be safe. We want to give these drugs safely. So, we have to assess our patients and make sure that this is an appropriate patient to give this therapy to. I think that's an open conversation that clinicians need to have with patients regarding these drugs." TS 18:08

Aiyana is an office worker with chronic low back pain who is referred to physical therapy. During a core stability assessment, the patient demonstrates difficulty maintaining a neutral pelvis while lifting one leg in a hook-lying position. Which muscle is MOST likely underperforming?A) IliopsoasB) Erector SpinaeC) Quadratus lumborumD) Rectus abdominisTEXT OUR TEAM:(727) 732-4573